TMCnet News
Research and Markets: NASH Is Currently The Third Most Common Factor Leading to Liver Transplants in the US, 2015 Report SaysResearch and Markets (http://www.researchandmarkets.com/research/7x6ssw/nash_drugs) has announced the addition of the "NASH Drugs Market, 2015 - 2025" report to their offering. The 'NASH Drugs Market, 2015-2025' report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of molecules in this area. With an expanding NAFLD and NASH population worldwide, there is a growing need for development of therapeutics in this disease area. NASH is gradually emerging as the leading cause of liver transplants. While the field has garnered interest of several companies, there are no approved therapies to date. It is important to stress that the development pipeline of NASH has several promising candidates that are likely to result in many commercial success stories in the foreseen future. Amongst other elements, the report elaborates on the new diagnostic solutions being developed and the upcoming opportunities for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area,one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analyzing:
Key Topics Covered
Companies Mentioned Partial list of the 70+ companies featured in this comprehensive report:
Full list available at http://www.researchandmarkets.com/research/7x6ssw/nash_drugs View source version on businesswire.com: http://www.businesswire.com/news/home/20150923005659/en/ |